Metformin controlled release tablet

A metformin and controlled-release tablet technology, which can be used in medical preparations with non-active ingredients, pill delivery, metabolic diseases, etc., and can solve problems such as increased osmotic pressure, increased incidence of adverse reactions, and increased metformin release.

Inactive Publication Date: 2010-12-15
冯岩
View PDF4 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of this technology is that because the metformin in the tablet core is easily soluble in water, and the tablet core contains a solubilizer that promotes the dissolution of metformin, it is easy to cause the local metformin in the tablet core to dissolve too quickly during the release process so that the inside of the coating film The osmotic pressure rises rapidly, and in this case, the release of metformin will suddenly increase, which will easily increase the incidence of adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metformin controlled release tablet
  • Metformin controlled release tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Tablet Prescription:

[0060] Component

[0061] Magnesium stearate

[0062] Tablet preparation method:

[0063] 1. Take metformin and pass through an 80-mesh sieve;

[0064] 2. Weigh metformin, polyoxyethylene, povidone k90, and sodium lauryl sulfate according to the prescription amount, mix well, add an appropriate amount of water-based soft material, pass through a 20-mesh sieve to granulate, and dry completely by blasting at 40°C;

[0065] 3. After the granules are completely dried, sieve the granules with a 20-mesh sieve, mix them evenly with the prescribed amount of magnesium stearate, and press them into tablets.

[0066] Coating solution prescription (1000ml coating solution dosage)

[0067] Cellulose acetate 30g

[0068] Macrogol 1500 4g

[0069] Triethyl citrate 3g

[0070] Acetone 900ml

[0071] water 100ml

[0072] Preparation method:

[0073] 1. Weigh 4g of polyethylene glycol 1500, add 100ml of water, soak to dissolve completely...

Embodiment 2

[0086] Tablet Prescription:

[0087] Component

[0088] Tablet cores were prepared according to the tablet core preparation method in Example 1 according to the prescription quantity of tablet cores, and the same coating solution as in Example 1 was used, and the same coating and punching method as in Example 1 was used to prepare metformin controlled release in this example. finished piece.

[0089] Release test results

[0090] time

[0091] 14h

Embodiment 3

[0093] Tablet Prescription:

[0094] Component

Content mg / tablet

percentage

Metformin

1000

83.5%

Povidone K90

62.5

5%

Sodium dodecyl sulfate

12.5

1%

Polyoxyethylene N80

62.5

5%

Magnesium stearate

68.75

5.5%

[0095] Tablet cores were prepared according to the tablet core preparation method in Example 1 according to the prescription quantity of tablet cores, and the same coating solution as in Example 1 was used, and the same coating and punching method as in Example 1 was used to prepare metformin controlled release in this example. finished piece.

[0096] Release test results

[0097] time

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a metformin controlled release tablet compound which contains an effective dose of metformin and polyoxyethylene and selectively contains or excludes one or more pharmaceutically acceptable auxiliary materials. The invention also relates to a metformin controlled release tablet which comprises a single-layer tablet core and a coating membrane covering the tablet core, wherein medicine release hole(s) is / are arranged on one side or two sides of each tablet, the tablet core contain an effective dose of the metformin and the polyoxyethylene and selectively contains one or more pharmaceutically acceptable auxiliary materials, and the coating membrane is a semi-permeable membrane.

Description

technical field [0001] The present invention relates to pharmaceutical preparation technology. More specifically, the present invention relates to a metformin controlled-release tablet composition, a metformin controlled-release tablet and their preparation methods. Background technique [0002] Metformin, a biguanide hypoglycemic agent, can improve blood sugar tolerance in patients with type 2 diabetes and reduce basal and postprandial blood sugar. The mechanism of action of metformin hydrochloride is different from other types of oral antiglycemic drugs. It can reduce the production of glycogen, reduce intestinal absorption of sugar, and improve insulin sensitivity by increasing the uptake and utilization of peripheral sugar. Unlike urea drugs, metformin hydrochloride does not produce hypoglycemia in patients with type 2 diabetes or in patients with normoglycemia. After metformin hydrochloride treatment, insulin secretion remained unchanged, but decreased fasting insulin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K9/28A61K9/44A61K47/34A61K47/38A61K31/155A61P3/10A61K47/10A61K47/26
Inventor 冯岩卢骏吴涛师键鑫
Owner 冯岩
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products